Sara Bongiovanni

Sara Bongiovanni

Auto-generated profile, based on publicly available information

Sara Bongiovanni

Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Current Pain and Headache Reports
Verified
Journal Article
Open access
PDF file
VGValeria Giorgi
Valeria Giorgi
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
GPGreta Pellegrino
Greta Pellegrino
SSSilvia Sirotti
Silvia Sirotti
FAFabiola Atzeni
Fabiola Atzeni
SBSara Francesca Bongiovanni
Sara Francesca Bongiovanni
Purpose of Review: Fibromyalgia Syndrome (FMS) is a complex chronic pain condition characterized by widespread musculoskeletal pain and numerous other debilitating symptoms. The purpose of this review is to provide a comprehensive overview, based on everyday clinical practice, of the drugs presently employed in the treatment of FMS. Recent Findings: The treatment of FMS is based on a multimodal approach, with pharmacologic treatment being an essential pillar. The drugs used include tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, other antidepressants, anticonvulsants, myorelaxants, and analgesics. The effectiveness of these medications varies, and the choice of drug often depends on the specific symptoms presented by the patient. Many drugs tend to either address only some domains of the complex FMS symptomatology or have a limited effect on pain. Summary: Each treatment option comes with potential side effects and risks that necessitate careful consideration. It may be beneficial to divide patients into clinical subpopulations, such as FMS with comorbid depression, for more effective treatment. Despite the complexities and challenges, the pharmacological treatment remains a crucial part for the management of FMS. This review aims to guide clinicians in prescribing pharmacological treatment to individuals with FMS.


10 March 2022 in Clinical and Experimental Rheumatology
Verified
Journal Article
Open access
Michael TentiMichael Tenti
Michael Tenti
WRWilliam Raffaeli
William Raffaeli
VMValentina Malafoglia
Valentina Malafoglia
MPMery Paroli
Mery Paroli
SISara Ilari
Sara Ilari
PGPaola Gremigni
Paola Gremigni
Full Papers; Authors: M. Tenti, W. Raffaeli, V. Malafoglia, M. Paroli, S. Ilari, C. Muscoli, E. Fraccaroli, S. Bongiovanni, C. Gioia, C. Iannuccelli, M. Di Franco, P. Gremigni